Related Experiment Video

Updated: Jun 18, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Hematology: dasatinib regimens for patients with chronic myeloid leukemia

François Guilhot1, Lydia Roy

  • 1Department of Oncology, Hematology, and Cell Therapy, Bone Marrow Transplant Unit, Centre Hospitalier Universitaire de Poitiers, France. fr.guilhot@wanadoo.fr

Nature Reviews. Clinical Oncology
|November 28, 2009
PubMed

Insights

Second-line dasatinib therapy offers a well-tolerated option for chronic myeloid leukemia patients resistant to imatinib mesylate. This tyrosine kinase inhibitor achieves high response rates in advanced-phase disease.

Area of Science:

  • Oncology
  • Hematology

Background:

  • Imatinib mesylate has improved outcomes for advanced chronic myeloid leukemia (CML).
  • Resistance to imatinib mesylate necessitates alternative therapeutic strategies.
  • Tyrosine kinase inhibitors (TKIs) are being evaluated as second-line treatments for CML.

Discussion:

  • Dasatinib, a TKI, demonstrates efficacy in imatinib-resistant CML.
  • Once-daily administration of dasatinib 140 mg is associated with good tolerability.
  • High response rates were observed in patients receiving dasatinib.

Key Insights:

  • Dasatinib is a promising second-line therapy for advanced CML.
  • Effective management of imatinib-resistant CML is achievable with TKIs.
  • Patient tolerance and response rates are critical metrics for evaluating CML treatments.

Outlook:

  • Further research into optimal TKI sequencing in CML is warranted.
  • Dasatinib's role in overcoming imatinib resistance requires continued investigation.
  • Long-term outcomes for patients treated with second-line dasatinib need to be established.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...